TC Biopharm (Holdings) Plc
TCBP · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.83 | 5.33 | -0.01 | 251.61 |
| FCF Yield | -4.32% | -2.22% | -0.06% | -0.02% |
| EV / EBITDA | -18.06 | 155.63 | -913.35 | -2,647.68 |
| Quality | ||||
| ROIC | -267.99% | -168.27% | 132.46% | -160.95% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.79 | 11.64 | 0.41 | 0.63 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 24.78% | -16.73% | 1,255,323.69% |
| Free Cash Flow Growth | 31.40% | -177.32% | -61.56% | 60.41% |
| Safety | ||||
| Net Debt / EBITDA | 0.05 | -0.53 | -1.33 | -0.35 |
| Interest Coverage | 0.00 | -1.79 | -2.12 | -23.58 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |